Grace’s SILSOL® technology offers solutions for poorly soluble active ingredients. Based on compendial silica and fully scalable, it gives pharmaceutical developers new options to enhance bioavailability of BCS2 compounds, especially during early research and discovery. For more information, visit silicadrugdelivery.com
